Navigation Links
ImmuneRegen BioSciences Announces Promising Data on Homspera,Suggesting Potential as a Co-Therapeutic Agent

ated mechanism by which vaccine adjuvants accomplish their immunosensitization. Additionally, the anti-anthrax activity reported by Homspera is similarly consistent with activation of components of innateimmunity that have been reported to have anti-anthrax activity, such as defensins. "While these results from the use of Homspera are preliminary, we believe that upcoming studies in non-human primates may provide confirmation that Homspera could play an important role, in conjunction with other therapies, in improving treatment outcomes in influenza and cancer, two large- market opportunities," said ImmuneRegen's CEO Michael Wilhelm. "With the pharmaceutical and biotechnology industries increasingly focused on adjunctive therapies, we are committed to accelerating development of this promising compound."

Since the identification of a single therapeutic with both immunoadjuvant capabilities plus the ability to enhance maturation and mobility of stem cells might be of significant therapeutic significance, the Company plans future studies to explore this opportunity in more detail.

About ImmuneRegen BioSciences, Inc.

IR BioSciences Holdings Inc., through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is a development stage biotechnology company focused on the research and development of Homspera(TM) and its derivatives Radilex(TM) and Viprovex(TM), which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera is derived from modified Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of improving pulmonary function and the stimulation of the human immune system. For more information, please visit the company's website at www.immuneregen.com.

Statements about the Company's future expectations, including statements about the potential for the Company's drug candidates, sci
'"/>




Page: 1 2 3 4

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
5. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
6. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
7. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
8. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:1/23/2015)... Jan. 23, 2015 Cord Blood America, Inc. ( www.cordblood-america.com ... the "Company")  filed a Preliminary Proxy Statement, Schedule 14A, with ... and provides an update for shareholders detailing why a "YES" ... Dear Shareholders, As we reflect upon ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft tissue ... Phase 2 clinical trial.  This open-label study will assess ... (an investigational medication), in approximately 30 adults as first-line ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 is ...
(Date:1/22/2015)... , Jan. 22, 2015  BiOptix is pleased to announce ... Vice President of Chemistry and Biochemistry. Scott joins the company ... Pharmaceuticals, and Amgen throughout the course of his nearly ... "Scott is a nationally recognized thought leader in ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... PARK, N.C. & GENEVA--(BUSINESS WIRE)--Jul 11,2007 ... research and,development program for Plasmin (Human), ... this week at the XXIst International,Society ... in Geneva,Switzerland. The information included new ...
... 2007 /PRNewswire/ -- Inspiration,Biopharmaceuticals today announced the ... new, proprietary forms of,recombinant Factor IX to ... highlighted in an oral presentation and a ... International Society on Thrombosis and,Haemostasis (ISTH) in ...
Cached Medicine Technology:New Information on the Potential of Plasmin Shared at ISTH Congress 2New Information on the Potential of Plasmin Shared at ISTH Congress 3New Information on the Potential of Plasmin Shared at ISTH Congress 4Inspiration Biopharmaceuticals Presents Data From Hemophilia,Program at International Society On Thrombosis and Haemostasis,(ISTH) Annual Meeting 2
(Date:1/22/2015)... (PRWEB) January 23, 2015 The U.S. ... R.Ph., DICVP, Director of Clinical Pharmacy Services at North ... the recipient of the 2015 Beal Award for Distinguished ... USP has relied on the contributions of volunteer experts ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Gabe’s Chemo Duck Program ... App, the first app ever created for kids with cancer. The ... phones and devices, is filled with enjoyable games to help children ... treatments. The free app helps to keep kids entertained, educated and ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) wants ... “Live Fearless.” , The “Faces of Fearless” campaign ... how they or someone they know has faced a challenge, ... moment. By telling these types of stories through livefearlessmn.com, participants ...
(Date:1/22/2015)... York (PRWEB) January 22, 2015 Thousand ... Fresenius Medical Care recalled its GranuFlo and NaturaLyte dialysis ... litigation underway in U.S. District Court, District of Massachusetts, ... January 20th, the Court has remanded a case filed ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... researchers have found that Alzheimers drug Donepezil may help ... ,Marcelo Berthier of the M dico-Sanitarias Research ... by boosting neurons ability to communicate. ,The ... people with aphasia, a condition characterised by an inability ...
... to talk in an effort to apprehend the appalling decline ... study revealed that half of the kids are not capable ... ,Therefore, ministers are promoting the use of ... initial months to age five, which makes the use of ...
... Disease (GIND) have discovered that reducing levels of ... deficits related to Alzheimer's disease. The findings, ... when tau is removed from mice genetically engineered ... retained and they live a normal lifespan. Reducing ...
... Matigara, Darjeeling District in West Bengal & Kuttanad in Kerala ... as per report received from High Animal Security Disease laboratory ... from these two places. ,In Matigara, unusual ... of 2500 birds on 5-6th May, 2007. A team headed ...
... are worried about falling rates in mammography use. According to ... Disease Control (CDC), the percentage of women taking the mammograms ... from 70 percent in 2000 to 66 percent in 2005. ... correspond with a fall in the use of hormone replacement ...
... makes your blood boil in anger, but as a new study ... a heart attack. ,Researchers base their findings on more ... London. ,As a part of the Whitehall Study II, ... statement: "I often have the feeling that I am being treated ...
Cached Medicine News:Health News:Toddlers to Be Trained to Improve Their Communication Skills 2Health News:New Strategy Identified for Preventing Acute and Chronic Brain Disease 2Health News:Mammogram Rates On The Decline In America 2Health News:Heart Attack Risk Increased by Unfair Treatment 2
... the dynamic way to manage a contracture. ... effective in reducing contractures. Full ROM is ... therapies. Can also be used as a ... and soft tissue contractures. Use where ROM ...
Swedish Knee Cage -- hinged to track knee motion. Effective control of genu recurvatum (back knee or knee hyperextension). Fits left or right....
... designed to stabilize the knee in full ... the knee with cushioned straps, and is ... knee, even at full extension. Because of ... the Knee Immobilizer is ideal for post-op ...
... Unique in the Cryo/Cuff line, the ... cuff is filled directly with water and ... To ensure the optimal amount of compression, ... pressure after application. The cuff remains cold ...
Medicine Products: